{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:22:19Z","timestamp":1789125739873,"version":"build-2803163510"},"reference-count":99,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Gene therapy is undergoing continued clinical translation and technological development. This progress has been marked by regulatory approvals and broadened therapeutic indications across genetic, metabolic, and oncologic diseases and disorders. The field has evolved over decades from early viral-mediated gene addition to approaches capable of targeted editing, regulation, or replacement of genetic information. These systems include base and prime editors, epigenetic modulators, CRISPR-Cas, RNA therapeutics and programmable integration platforms. When paired with increasingly sophisticated viral and nonviral delivery strategies, these technologies enable greater control over tissue targeting, duration of activity, and therapeutic exposure. Recent clinical successes, including approved ex vivo CRISPR-based therapies for hemoglobinopathies, in vivo CRISPR editing for transthyretin amyloidosis, and emerging clinical applications of base and prime editing, provide growing clinical evidence for the feasibility of genetic medicines. However, technological advancement has also made platform selection increasingly complex. Therapeutic performance is determined not by editing efficiency alone, but by the interaction among genetic precision, temporal control, dosage tunability, delivery efficiency, durability, and disease-specific safety requirements. A molecularly efficient platform may still have limited therapeutic value if it cannot reach the disease-relevant cell population at sufficient and safe exposure. In this review, we examine recent technological and clinical advances in genetic medicine with particular emphasis on developments during the past approximately five years. We propose a multidimensional framework in which gene therapy platforms are evaluated according to three intrinsic properties\u2014genetic precision, temporal control, and dosage tunability\u2014while delivery, clinical maturity, and disease context act as major translational constraints. This framework highlights that no single platform is universally optimal; rather, successful therapeutic design depends on matching the biological characteristics of the intervention to the requirements of the disease and target tissue. Remaining challenges in extrahepatic delivery, genomic safety, immunogenicity, manufacturing, and long-term monitoring remain important determinants of broader clinical implementation.<\/jats:p>","DOI":"10.3390\/cells15181647","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:51:37Z","timestamp":1789123897000},"page":"1647","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Precision: A Multidimensional Framework for Selecting Genetic Medicine Platforms"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1581-5039","authenticated-orcid":false,"given":"Jared","family":"Wieland","sequence":"first","affiliation":[{"name":"Department of Cell Biology & Physiology, Brigham Young University, Provo, UT 84602, USA"},{"name":"Indel Bioinnovations, Provo, UT 84602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyton","family":"Jackson","sequence":"additional","affiliation":[{"name":"Indel Bioinnovations, Provo, UT 84602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Penrod","sequence":"additional","affiliation":[{"name":"Department of Cell Biology & Physiology, Brigham Young University, Provo, UT 84602, USA"},{"name":"Indel Bioinnovations, Provo, UT 84602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Nadauld","sequence":"additional","affiliation":[{"name":"Department of Cell Biology & Physiology, Brigham Young University, Provo, UT 84602, USA"},{"name":"Indel Bioinnovations, Provo, UT 84602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-9009","authenticated-orcid":false,"given":"Jared","family":"Barrott","sequence":"additional","affiliation":[{"name":"Department of Cell Biology & Physiology, Brigham Young University, Provo, UT 84602, USA"},{"name":"Indel Bioinnovations, Provo, UT 84602, USA"},{"name":"Simmons Center for Cancer Research, Brigham Young University, Provo, UT 84602, USA"},{"name":"School of Medicine, Brigham Young University, Provo, UT 84602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41591-021-01650-w","article-title":"Long-term outcomes of lentiviral gene therapy for the \u03b2-hemoglobinopathies: The HGB-205 trial","volume":"28","author":"Magrin","year":"2022","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.aba8853","article-title":"Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants","volume":"368","author":"Walton","year":"2020","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41587-020-0412-8","article-title":"Continuous evolution of SpCas9 variants compatible with non-G PAMs","volume":"38","author":"Miller","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.molcel.2020.02.023","article-title":"Highly Parallel Profiling of Cas9 Variant Specificity","volume":"78","author":"Gao","year":"2020","journal-title":"Mol. Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.aav9023","article-title":"Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq","volume":"364","author":"Wienert","year":"2019","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nmeth.4284","article-title":"Mapping the genomic landscape of CRISPR-Cas9 cleavage","volume":"14","author":"Cameron","year":"2017","journal-title":"Nat. Methods"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41587-020-0555-7","article-title":"CHANGE-seq reveals genetic and epigenetic effects on CRISPR-Cas9 genome-wide activity","volume":"38","author":"Lazzarotto","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kim, D., and Kim, J.-S. (2020). Profiling Genome-wide specificity of CRISPR-Cas9 using digenome-seq. CRISPR Guide RNA Design: Methods and Protocols, Springer US.","DOI":"10.1007\/978-1-0716-0687-2_13"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1902312","DOI":"10.1002\/advs.201902312","article-title":"CRISPR\/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off-Target Evaluation, and Strategies to Mitigate Off-Target Effects","volume":"7","author":"Manghwar","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","article-title":"Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1093\/nar\/gkw159","article-title":"Repurposing the CRISPR-Cas9 system for targeted DNA methylation","volume":"44","author":"Vojta","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cell.2016.09.006","article-title":"Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing","volume":"167","author":"Amabile","year":"2016","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/nar\/gkw1112","article-title":"Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase","volume":"45","author":"Stepper","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1093\/nar\/gkac123","article-title":"Determinants of heritable gene silencing for KRAB-dCas9+ DNMT3 and Ezh2-dCas9+ DNMT3 hit-and-run epigenome editing","volume":"50","author":"Tomkova","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.1038\/s41467-025-63167-x","article-title":"Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_29","first-page":"101151","article-title":"mRNA-engineered CRISPR-Cas epigenetic editors enable durable and efficient gene silencing in vivo","volume":"7","author":"Xu","year":"2026","journal-title":"Innovation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1038\/s41467-024-50555-y","article-title":"Systematic multi-trait AAV capsid engineering for efficient gene delivery","volume":"15","author":"Eid","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.omtm.2020.12.006","article-title":"Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning","volume":"20","author":"Nonnenmacher","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Brown, D., Altermatt, M., Dobreva, T., Chen, S., Wang, A., Thomson, M., and Gradinaru, V. (2021). Deep Parallel Characterization of AAV Tropism and AAV-Mediated Transcriptional Changes via Single-Cell RNA Sequencing. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.730825"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41592-020-0799-7","article-title":"Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types","volume":"17","author":"Miles","year":"2020","journal-title":"Nat. Methods"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27053","DOI":"10.1073\/pnas.1910061116","article-title":"A systematic capsid evolution approach performed in vivo for the design of AAV vectors with tailored properties and tropism","volume":"116","author":"Davidsson","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2022","journal-title":"Nat. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mus.27955","article-title":"Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1\/2a nonrandomized trial","volume":"69","author":"Mendell","year":"2024","journal-title":"Muscle Nerve"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: The EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-019-09006-2","article-title":"CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations","volume":"10","author":"Cullot","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00439-023-02561-1","article-title":"Unintended CRISPR-Cas9 editing outcomes: A review of the detection and prevalence of structural variants generated by gene-editing in human cells","volume":"142","author":"Hunt","year":"2023","journal-title":"Hum. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11596-026-00178-9","article-title":"Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy","volume":"46","author":"Wang","year":"2026","journal-title":"Curr. Med. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e143780","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.ymthe.2022.05.004","article-title":"AAV vector manufacturing process design and scalability-Bending the trajectory to address vector-associated immunotoxicities","volume":"30","author":"Wright","year":"2022","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Parajuli, S., Gallagher, T., and Flotte, T.R. (2026). Immune Toxicities in AAV Gene Therapy: Overview for Clinicians. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27073196"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41586-020-03086-7","article-title":"In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice","volume":"589","author":"Koblan","year":"2021","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41587-020-0491-6","article-title":"Directed evolution of adenine base editors with increased activity and therapeutic application","volume":"38","author":"Gaudelli","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","article-title":"Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity","volume":"38","author":"Richter","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1016\/j.cell.2023.07.039","article-title":"Phage-assisted evolution and protein engineering yield compact, efficient prime editors","volume":"186","author":"Doman","year":"2023","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/s41467-021-21559-9","article-title":"Programmable C:G to G:C genome editing with CRISPR-Cas9-directed base excision repair proteins","volume":"12","author":"Chen","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41587-020-0609-x","article-title":"CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells","volume":"39","author":"Kurt","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cell.2020.05.037","article-title":"Determinants of Base Editing Outcomes from Target Library Analysis and Machine Learning","volume":"182","author":"Arbab","year":"2020","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","article-title":"Engineered pegRNAs improve prime editing efficiency","volume":"40","author":"Nelson","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","article-title":"Enhanced prime editing systems by manipulating cellular determinants of editing outcomes","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41587-023-02050-w","article-title":"Glycosylase-based base editors for efficient T-to-G and C-to-G editing in mammalian cells","volume":"42","author":"Ye","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41587-021-01026-y","article-title":"Deletion and replacement of long genomic sequences using prime editing","volume":"40","author":"Jiang","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","article-title":"Efficient prime editing in mouse brain, liver and heart with dual AAVs","volume":"42","author":"Davis","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"eabl9238","DOI":"10.1126\/scitranslmed.abl9238","article-title":"In vivo prime editing of a metabolic liver disease in mice","volume":"14","author":"Rothgangl","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41551-023-01026-0","article-title":"Ex vivo prime editing of patient haematopoietic stem cells rescues sickle-cell disease phenotypes after engraftment in mice","volume":"7","author":"Everette","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41551-021-00788-9","article-title":"Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases","volume":"6","author":"Jang","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41587-025-02568-1","article-title":"The reverse transcriptase domain of prime editors contributes to DNA repair in mammalian cells","volume":"44","author":"Zheng","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41587-021-01133-w","article-title":"Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing","volume":"40","author":"Anzalone","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases","volume":"41","author":"Yarnall","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41551-024-01227-1","article-title":"Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing","volume":"9","author":"Pandey","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","article-title":"A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice","volume":"53","author":"Hogan","year":"2020","journal-title":"Immunity"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"eabc9450","DOI":"10.1126\/sciadv.abc9450","article-title":"CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41587-024-02437-3","article-title":"Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR-Cas9 ribonucleoprotein","volume":"43","author":"Chen","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e1807748","DOI":"10.1002\/adma.201807748","article-title":"Nanoparticles Containing Oxidized Cholesterol Deliver mRNA to the Liver Microenvironment at Clinically Relevant Doses","volume":"31","author":"Paunovska","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2116271119","DOI":"10.1073\/pnas.2116271119","article-title":"Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis","volume":"119","author":"Qiu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41563-025-02320-9","article-title":"Tissue-specific mRNA delivery and prime editing with peptide-ionizable lipid nanoparticles","volume":"25","author":"Lin","year":"2026","journal-title":"Nat. Mater."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"E9944","DOI":"10.1073\/pnas.1811276115","article-title":"High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing","volume":"115","author":"Sago","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1126\/science.aax9181","article-title":"RNA-guided DNA insertion with CRISPR-associated transposases","volume":"365","author":"Strecker","year":"2019","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41586-022-05573-5","article-title":"Structures of the holo CRISPR RNA-guided transposon integration complex","volume":"613","author":"Park","year":"2023","journal-title":"Nature"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41586-019-1849-0","article-title":"Structural basis of DNA targeting by a transposon-encoded CRISPR-Cas system","volume":"577","author":"Klompe","year":"2020","journal-title":"Nature"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"eadt5199","DOI":"10.1126\/science.adt5199","article-title":"Programmable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase","volume":"388","author":"Witte","year":"2025","journal-title":"Science"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41587-022-01574-x","article-title":"Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases","volume":"41","author":"Tou","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41587-020-00745-y","article-title":"CRISPR RNA-guided integrases for high-efficiency, multiplexed bacterial genome engineering","volume":"39","author":"Vo","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa2505478","article-title":"Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia","volume":"394","author":"Chiesa","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"eadi1145","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","article-title":"Non-viral precision T cell receptor replacement for personalized cell therapy","volume":"615","author":"Foy","year":"2023","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2601283","article-title":"In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia","volume":"395","author":"Vafai","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa2509807","article-title":"Prime Editing for p47phox-Deficient Chronic Granulomatous Disease","volume":"394","author":"Gori","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2501277","article-title":"CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat \u03b2-Thalassemia","volume":"394","author":"Frangoul","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_97","unstructured":"U.S. Food and Drug Administration (2024). Human Gene Therapy Products Incorporating Human Genome Editing: Guidance for Industry, Center for Biologics Evaluation and Research."},{"key":"ref_98","unstructured":"U.S. Food and Drug Administration (2026). Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing: Draft Guidance for Industry, Center for Biologics Evaluation and Research."},{"key":"ref_99","unstructured":"U.S. Food and Drug Administration (2026). Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing: Draft Guidance for Industry, Center for Biologics Evaluation and Research."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/18\/1647\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:03:29Z","timestamp":1789124609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/18\/1647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":99,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cells15181647"],"URL":"https:\/\/doi.org\/10.3390\/cells15181647","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}